Flag of the European Union EU Clinical Trials Register Help

Clinical trials for skin cancer in Australia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    134 result(s) found for: skin cancer in Australia. Displaying page 5 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-000518-37 Sponsor Protocol Number: 580299/013 Start Date*: 2004-08-27
    Sponsor Name:GlaxoSmithKline AS
    Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly according t...
    Medical condition: cervical cancer: the study is conducted in healthy female adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: NO (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002521-30 Sponsor Protocol Number: HBI-8000-303 Start Date*: 2022-03-07
    Sponsor Name:HUYABIO International, LLC
    Full Title: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated w...
    Medical condition: Metastatic or unresectable melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003456-36 Sponsor Protocol Number: CL1-95012-001 Start Date*: 2021-08-09
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors
    Medical condition: Advanced and/or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004453-23 Sponsor Protocol Number: R3767-ONC-2011 Start Date*: 2022-08-30
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
    Medical condition: Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003351-37 Sponsor Protocol Number: I4V-MC-JAJA Start Date*: 2019-08-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) HU (Completed) DE (Restarted) GR (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015476-98 Sponsor Protocol Number: 1200.75 Start Date*: 2010-05-17
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one pri...
    Medical condition: patients with metastatic HER2 over-expressing breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) FR (Completed) AT (Completed) IT (Completed) ES (Completed) FI (Prematurely Ended) LT (Completed) LV (Completed) SI (Completed) GB (Completed) IE (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2008-005127-29 Sponsor Protocol Number: TAX_GMA_302 Start Date*: 2001-05-21
    Sponsor Name:SANOFI-AVENTIS
    Full Title: MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTI...
    Medical condition: node positive and high risk node negative patients with operable breast cancer containing the the HER2 alteration.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004554-30 Sponsor Protocol Number: LOXO-BTK-20020 Start Date*: 2021-06-04
    Sponsor Name:Loxo Oncology Inc
    Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/...
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000051-16 Sponsor Protocol Number: JX594-HEP018 Start Date*: 2012-12-21
    Sponsor Name:Jennerex, Inc
    Full Title: A Phase 2b Randomized Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Wh...
    Medical condition: Advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004011-24 Sponsor Protocol Number: GO27826 Start Date*: 2012-09-14
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR REC...
    Medical condition: Melanoma (patients with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma or patients with Stage IIIC cutaneous melanoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025669 Malignant melanoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) CZ (Completed) DE (Completed) FR (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) EE (Completed) PT (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003380-95 Sponsor Protocol Number: CDYP688A12101 Start Date*: 2022-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
    Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) NO (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001984-35 Sponsor Protocol Number: M16OPN Start Date*: 2017-06-22
    Sponsor Name:Antoni van leeuwenhoek ziekenhuis
    Full Title: Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
    Medical condition: Patients with stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003064-27 Sponsor Protocol Number: PH-L19IL2TNF-01/18 Start Date*: 2022-02-25
    Sponsor Name:Philogen S.p.A.
    Full Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and ...
    Medical condition: Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004594-32 Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 Start Date*: 2022-02-16
    Sponsor Name:IO Biotech ApS
    Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv...
    Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000043-49 Sponsor Protocol Number: LOXO-BTK-20022 Start Date*: 2021-08-16
    Sponsor Name:Loxo Oncology Inc
    Full Title: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Sm...
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NO (Completed) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000359-15 Sponsor Protocol Number: DZB-CS-201 Start Date*: 2020-02-11
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)
    Medical condition: urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001282-40 Sponsor Protocol Number: MORAb-004-201-Mel Start Date*: 2011-09-22
    Sponsor Name:Morphotek Inc
    Full Title: A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma
    Medical condition: Metastaic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-000317-78 Sponsor Protocol Number: PV-10-MM-31 Start Date*: 2017-02-24
    Sponsor Name:PROVECTUS BIOPHARMACEUTICALS, INC.
    Full Title: PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
    Medical condition: Locally Advanced Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003008-11 Sponsor Protocol Number: GO28141 Start Date*: 2013-02-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ...
    Medical condition: BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) AT (Completed) NO (Completed) DE (Completed) BE (Completed) SE (Completed) IT (Completed) NL (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001492-16 Sponsor Protocol Number: M21NDN Start Date*: 2021-06-16
    Sponsor Name:NKI-AVL
    Full Title: Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA
    Medical condition: Patients with stage III melanoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 10:52:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA